Azar’s Plan To Tie U.S. Drug Prices To Foreign Ones Will Impact Investments In R&D

Publish date: June 21, 2019

By John LaMattina,  Contributor for Forbes

Azar claims that HHS can reduce spending on Medicare Part B drugs with little impact on biopharmaceutical R&D investment. Duane Schulthess, Managing Director at VitalTransformation, questioned Azar’s claim on this. As he delved into specific compounds on Azar’s list of 27, he found some startling data. One striking case is with Biogen’s Multiple Sclerosis drug, Tysabri.

You can read the full story on Forbes